News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
209,194 Results
Type
Article (11892)
Company Profile (116)
Press Release (197186)
Section
Business (59740)
Career Advice (407)
Deals (9285)
Drug Delivery (21)
Drug Development (30782)
Employer Resources (43)
FDA (3735)
Job Trends (4863)
News (101785)
Policy (8151)
Tag
Academia (972)
Africa (299)
Alliances (16689)
Alzheimer's disease (406)
Approvals (3711)
Arizona (26)
Artificial intelligence (21)
Asia (12301)
Australia (2701)
Bankruptcy (67)
Best Places to Work (4066)
Biotechnology (96)
Breast cancer (21)
C2C Services and Suppliers (10374)
California (892)
Canada (383)
Cancer (201)
Career advice (372)
CAR-T (21)
Cell therapy (79)
China (43)
Clinical research (22489)
Collaboration (85)
Compensation (21)
Connecticut (35)
COVID-19 (2139)
Cystic fibrosis (35)
Data (168)
Diagnostics (1738)
Drug discovery (23)
Earnings (18378)
Employer resources (38)
Europe (28121)
Events (43661)
Executive appointments (82)
FDA (3824)
Florida (108)
Funding (62)
Gene editing (22)
Gene therapy (51)
GLP-1 (141)
Government (1588)
Healthcare (5261)
Hotbed/Location (146908)
Idaho (21)
Illinois (101)
Indiana (60)
Infectious disease (2176)
Inflammatory bowel disease (42)
Interviews (51)
IPO (4598)
Job creations (904)
Job search strategy (336)
Layoffs (63)
Legal (1322)
Manufacturing (43)
Maryland (161)
Massachusetts (680)
Medical device (2227)
Medtech (2227)
Mergers & acquisitions (4712)
Metabolic disorders (62)
Michigan (51)
Minnesota (59)
Neuroscience (464)
New Jersey (283)
New York (246)
NextGen Class of 2024 (1593)
Non-profit (1217)
North Carolina (233)
Northern California (392)
Obesity (35)
Ohio (46)
Opinion (59)
Patents (29)
Pennsylvania (251)
People (20435)
Phase I (8277)
Phase II (10536)
Phase III (6450)
Pipeline (67)
Postmarket research (571)
Preclinical (3861)
Press Release (54)
Radiopharmaceuticals (56)
Rare diseases (55)
Real estate (1879)
Regulatory (5605)
Research institute (826)
Resumes & cover letters (40)
RSV (22)
South America (367)
Southern California (384)
Startups (1291)
Texas (93)
United States (3629)
Vaccines (365)
Virginia (28)
Washington State (191)
Weight loss (24)
Date
Last 7 days (265)
Last 30 days (1008)
Last 365 days (13886)
2024 (10584)
2023 (15077)
2022 (21221)
2021 (26949)
2020 (24461)
2019 (11269)
2018 (8686)
2017 (8751)
2016 (8375)
2015 (9434)
2014 (7256)
2013 (5915)
2012 (6449)
2011 (7131)
2010 (6527)
209,194 Results for "vir biotechnology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT.
May 23, 2024
·
1 min read
FDA
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designatio.
June 26, 2024
·
7 min read
Business
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
May 2, 2024
·
19 min read
Biotech Bay
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024.
May 29, 2024
·
5 min read
Biotech Bay
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET.
April 30, 2024
·
1 min read
Earnings
Vir Lays Off 25% of Staff, Abandons Most Virus Work and Pivots to Cancer in Sanofi Deal
As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.
August 2, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, at 11:00 a.m. PT / 2:00 p.m. ET at the Loews Miami Beach Hotel, Miami Beach, Florida.
May 29, 2024
·
1 min read
Biotech Bay
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation.
May 21, 2024
·
5 min read
Biotech Bay
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company’s chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8.
May 22, 2024
·
7 min read
News
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 3, 2024
·
1 min read
1 of 20,920
Next
